Molecular Formula | C17H14N2O3 |
Molar Mass | 294.3 |
Solubility | DMSO: ≥ 32 mg/mL |
Storage Condition | under inert gas (nitrogen or Argon) at 2-8°C |
In vitro study | PHCCC potentiated the effect of L-(+)-2-amino-4-phosphonobutyric acid (L-AP4) in inhibiting transmission at the striatopallidal synapse. |
In vivo study | PHCCC (75 nmol/2.5 μl; intracerebroventricular) produces an antiparkinsonian effect in a dopamine depletion akinesia model. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 3.398 ml | 16.989 ml | 33.978 ml |
5 mM | 0.68 ml | 3.398 ml | 6.796 ml |
10 mM | 0.34 ml | 1.699 ml | 3.398 ml |
5 mM | 0.068 ml | 0.34 ml | 0.68 ml |
biological activity | PHCCC is a type I mGluR (Group I mGluR) antagonist with an IC50 of 3 μm, PHCCC is also a selective positive modulator of the mGlu4 receptor. Has Anti-Parkinson's disease effect. |